Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2–Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors
Year: 2010
Type: article
Study design: Clinical Trial
Source: Clinical Cancer Research
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
Funder: Amgen
OpenAlex ID: W2132827381
